NiKang Therapeutics
PrivateLast Round
Series C
May 26, 2021
Total Funding Raised
$270M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
NiKang Therapeutics operates in Healthcare & Life Sciences and is based in Wilmington, Delaware. Its latest recorded funding round was a Series C round in May 2021.
NiKang Therapeutics is a biotechnology company that discovers and develops innovative small molecule oncology medicines to address unmet medical needs through structure-based drug design.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NiKang Therapeutics Comparables
Compare NiKang Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BlossomHill Therapeutics | 82% | |
| Avenzo Therapeutics | 78% | |
| Arcus Biosciences | 77% |
For institutional investors. Book with your work email.
NiKang Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | May 26, 2021 | ||||
| Series B | Sep 14, 2020 | ||||
| Seed | Dec 4, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
NiKang Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Series C |
| Matrix | Series B, Series C |
| Surveyor Capital | Series C |
| Janus Henderson Group | Series C |
| RA Capital Management | Series C |
| Perceptive Advisors | Series C |
| Octagon Capital Advisors | Series B, Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 47% MoM.
- Jun 18, 2026
Monthly visitors increased 96% MoM.
For institutional investors. Book with your work email.
NiKang Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about NiKang Therapeutics's valuation, stock price, and market status.
Is NiKang Therapeutics a public or private company?
NiKang Therapeutics is a private company.
What is the current stock price of NiKang Therapeutics?
NiKang Therapeutics is a private company, so its shares have no public market price. Caplight tracks NiKang Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NiKang Therapeutics worth (valuation)?
Valuation information for NiKang Therapeutics is not publicly available.
Can I buy NiKang Therapeutics stock?
NiKang Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NiKang Therapeutics's last funding round?
NiKang Therapeutics's most recent funding round was Series C on May 26, 2021.
Who are the main investors in NiKang Therapeutics?
Key investors in NiKang Therapeutics include Octagon Capital Advisors, Cormorant Asset Management, CBC Group, HBM Healthcare Investments, Octagon Capital Advisors.
Will NiKang Therapeutics IPO soon?
No public IPO plans have been announced for NiKang Therapeutics.
How can I track NiKang Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in NiKang Therapeutics's shares on secondary markets.